Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Mantle Cell Lymphoma Specialty Channel

Mantle Cell Lymphoma
Specialty Channel
FDA Approval
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
News
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology
News
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology
News
01/24/2024

Jordan Kadish

Jordan Kadish
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
Quiz
01/23/2024
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter,...
01/23/2024
Oncology

Advertisement

News

FDA Approval
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
News
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology
News
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology
News
01/24/2024

Jordan Kadish

Jordan Kadish
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
News
11/28/2023

Jordan Kadish

Jordan Kadish
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of...
11/28/2023
Oncology
News
11/28/2023

Jordan Kadish

Jordan Kadish
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative...
11/28/2023
Oncology
News
11/06/2023

Jordan Kadish

Jordan Kadish
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a...
11/06/2023
Oncology
News
11/06/2023

Jordan Kadish

Jordan Kadish
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen...
11/06/2023
Oncology

Interactive Features

Quiz
01/23/2024
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter,...
01/23/2024
Oncology
Quiz
12/05/2023
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to...
12/05/2023
Oncology
Quiz
12/01/2023
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19...
12/01/2023
Oncology
Quiz
11/27/2023
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the...
11/27/2023
Oncology
Quiz
11/21/2023
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up...
11/21/2023
Oncology
Quiz
11/14/2023
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an...
11/14/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement